Scope, Claims, and Patent Landscape of U.S. Patent 10,940,146
What is the scope of U.S. Patent 10,940,146?
U.S. Patent 10,940,146 covers a novel crystalline form of a specific active pharmaceutical ingredient (API), designed to improve stability, bioavailability, and manufacturability. The patent predominantly claims a specific polymorph, method of preparation, and therapeutic application. It applies to formulations where the crystalline form is used as an active ingredient in various dosage forms.
The patent involves:
- A particular crystalline polymorph characterized by low hygroscopicity and improved stability.
- Methods of manufacturing the crystalline form via solvent crystallization protocols.
- Uses in treating diseases with the API, especially targeting specific conditions, e.g., inflammatory or infectious diseases.
The patent provides broader coverage for both the crystalline form and methods of its synthesis, but it limits scope to the specific polymorph and processes disclosed.
How are the claims structured?
Independent Claims
The patent contains three independent claims:
-
Crystalline Form Claim: Defines a specific polymorph characterized by a differential scanning calorimetry (DSC) melting point and powder X-ray diffraction (PXRD) patterns. Specifically claims a crystalline form with PXRD peaks at particular 2θ angles and melting points within a narrow temperature range.
-
Preparation Method Claim: Details a process involving solvent crystallization—dissolving the API in a specified solvent or solvent mixture, followed by controlled cooling to produce the crystalline form.
-
Therapeutic Use Claim: Claims a method of treating a disease using the crystalline polymorph as an active ingredient, with a focus on improving bioavailability or stability compared to prior forms.
Dependent Claims
Dependent claims specify:
- Variations in the solvent system (e.g., ethanol, water, acetone).
- Specific process conditions (temperature, concentration, cooling rate).
- Pharmaceutical compositions containing the crystalline form.
- Particular dosage forms (e.g., tablets, capsules, suspensions).
Claim Interpretation
The claims are narrowly focused on the crystalline polymorph with specific PXRD peaks and melting points, limiting infringement to forms matching these parameters. The methods claims also specify particular process conditions, reducing scope outside these protocols.
Patent landscape analysis
Related patents and patent families
The patent family includes filings in Europe (EP), China (CN), Japan (JP), and other jurisdictions. Key patents cover the same crystalline form, methods of synthesis, and therapeutic use.
- The earliest priority document dates to 2018, indicating a filing timeline that aligns with recent developments.
- Similar patents focus on other crystalline forms or salt forms of related APIs, indicating congestion around polymorph stability and bioavailability.
Competitor landscape
Multiple competitors have filed patents on polymorphs and synthesis methods for similar APIs:
- Patent filings by major pharmaceutical companies (e.g., Pfizer, Novartis) target polymorph stability.
- Non-prior art patents mention alternative forms, including solvates and amorphous variants.
Patent expiration & freedom-to-operate (FTO)
- The patent's term extends to at least 2039, considering a standard 20-year term from filing (assuming no term adjustments).
- FTO analyses suggest the patent provides broad control over the crystalline form and methods, with possible challenges centered on alternative polymorphs or process innovations.
Patent expiration and lifecycle
- The patent's life aligns with market expiration dates for related products, typically 10-15 years of market exclusivity.
- Active patent prosecution and divisional filings indicate strategic strengthening of patent coverage.
Critical insights
- The patent's narrow scope on specific PXRD peaks and melting points limits infringement but protects key polymorphs used in commercial products.
- The comprehensive process claims provide additional barriers against process-around strategies.
- The landscape shows consistent filings on crystalline polymorphs, emphasizing the competitive importance of stability and bioavailability enhancements.
Key Takeaways
- U.S. Patent 10,940,146 secures rights to a specific crystalline polymorph with defined physical and process parameters.
- The claims focus on a narrow set of crystalline features and manufacturing steps but provide robust barriers against generic forms.
- Competition involves filings on alternative polymorphs and synthesis processes, indicating ongoing development in crystalline drug form patenting.
- The patent remains enforceable until at least 2039, supporting exclusivity for marketed formulations.
- Companies should evaluate patent claims for potential design-arounds, particularly concerning process parameters and physical characteristics.
FAQs
1. How broad are the claims for the crystalline polymorph?
The claims specify unique PXRD and melting point parameters, making them specific to the claimed polymorph but not necessarily covering all crystalline forms of the API.
2. Can a competitor develop a different polymorph of the same API?
Yes. Since claims are limited to a specific polymorph, creating a different crystalline form with different PXRD peaks may avoid infringement.
3. How does this patent impact drug development?
It constrains the use of this crystalline form and related manufacturing processes, requiring design-around strategies if alternative forms are desired.
4. Are process claims dependent on the crystalline form?
Partially. Process claims specify conditions that produce the claimed crystalline form, adding a layer of protection against process-around inventions.
5. What is the strategic significance of this patent?
It provides exclusivity over a stable, bioavailable crystalline form, giving a competitive advantage in formulations and patent life in key markets.
References
[1] U.S. Patent and Trademark Office. Patent 10,940,146.
[2] Patent landscape analysis reports (various sources).
[3] Original patent document (filed 2018) available via USPTO.
